ArticleHepatology international2021
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Article in Hepatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 5 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Association between the atherogenic index of plasma and metabolic-associated/nonalcoholic fatty liver disease: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Comparative association between NAFLD and MAFLD with cardiovascular events and mortality: Evidence from observational studies.PloS one · 2025Pooled it
- Does metabolic dysfunction-associated fatty liver disease increase the risk of chronic kidney disease? A meta-analysis of cohort studies.BMC nephrology · 2024Pooled it
- Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.Hepatology international · 2024Pooled it
- Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Comparison of Clinical Outcomes in Patients With Acute Myocardial Infarction Between Those With and Without Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).Circulation reports · 2026Article
- Metabolic dysfunction-associated steatotic liver disease in chronic hepatitis B patients: risks of severe liver disease and cardiovascular disease.Frontiers in cellular and infection microbiology · 2026Article
- The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease.Hepatology international · 2025Article
- [Metabolic-associated fatty liver disease (MAFLD): a multisystemic disease beyond the liver].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- The utility of an artificial intelligence model based on decision tree and evolution algorithm to evaluate steatotic liver disease in a primary care setting.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- Rifaximin prophylaxis in MASLD‑hepatocellular carcinoma: Lessons from a negative animal model.Biomedical reports · 2025Article
- Ultrasound Shear Wave Elastography Evaluation of the Liver and Implications for Perioperative Medicine.Journal of clinical medicine · 2024Review
- Muscle fibre morphometric analysis (MusMA) correlates with muscle function and cardiovascular risk prognosis.International journal of experimental pathology · 2024Article
- Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.Hepatobiliary surgery and nutrition · 2023Article
- Review
- NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care.Internal and emergency medicine · 2023Review
- Taurine alleviated hepatic steatosis in oleic acid-treated-HepG2 cells and rats fed a high-fat diet.Heliyon · 2023Article
- Article
- Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes.World journal of hepatology · 2023Review
- Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease.Diabetes & metabolism journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background/purposeCardiovascular disease (CVD) is the leading cause of death among individuals with non-alcoholic fatty liver disease (NAFLD). Recently, NAFLD was renamed metabolic-associated fatty liver disease (MAFLD). This study aimed to compare cardiovascular risk (CVR) and CVD between patients with NAFLD and MAFLD.
methodsRetrospective cross-sectional study of biopsy-proven liver steatosis performed between 2013 and 2018 at a university hospital. Cases were divided into NAFLD or MAFLD and demographic, clinical, and laboratory data were collected to assess CVR (through the atherosclerotic cardiovascular disease risk estimator and atherogenic indices) and CVD.
resultsOut of 1233 liver biopsies, 171 (13.9%) presented steatosis. Of these, 109 patients met diagnostic criteria for NAFLD (63.7%) and 154 (90.1%), for MAFLD. In the NAFLD group, 78% of the cases had steatohepatitis, 24.8% had cirrhosis, and 3.7%, hepatocellular carcinoma (HCC). In the MAFLD group, 72.7% of the cases had liver inflammatory activity, 28.6% had cirrhosis, and 13.6% had HCC. In patients with MAFLD and NAFLD, CVR was intermediate/high (36.4 and 25.7%, p = 0.209) and CVD occurred in 20.1 and 12.8% (p = 0.137) of the cases, respectively, with no influence of liver injury severity. We observed a significant increase in high 10-year CVR (p = 0.020) and CVD (p = 0.007) in patients with MAFLD and concomitant viral infection (HCV and/or HBV) compared to cases with MAFLD only.
conclusionPatients with both NAFLD and MAFLD had intermediate/high CVR, with a high rate of CVD. Patients with MAFLD and concomitant viral infection showed significantly increased CVR and CVD compared to those without viral infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.